The Latest

  • COUR Pharmaceuticals Announces Biotechnology Industry Veteran Robert F. Carey Joins Board of Directors as Lead Independent Director
  • Skip to primary navigation
  • Skip to main content
  • Skip to footer
COUR Pharmaceuticals Logo

COUR Pharmaceuticals

  • Our Company
    • Leadership
    • Advisors
    • Partners
    • Contact
  • Our Technology
    • Pipeline
    • Autoimmune Diseases
    • Allergies
    • Rare Diseases
    • Gene Therapy
  • Our Clinical Trials
  • Publications & Media
    • Press Releases
    • Publications
  • Careers
Video Poster

Reprogramming the Immune System

About COUR Who We Are

About COUR Who We Are

COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease. COUR’s platform of immune-modifying nanoparticles aims to treat the root cause of immune disease, unlike traditional approaches, which only minimize symptoms using toxic immune suppression. COUR’s lead product for celiac disease, partnered with Takeda, is the first demonstration of induction of antigen-specific immune tolerance in any autoimmune disease. Data from clinical and preclinical settings demonstrate the opportunity for the COUR nanoparticle platform to address a wide range of immune and inflammatory conditions.

Learn More About Our Technology

COUR Nanoparticle Platform Focuses On

Reprogramming the Immune System

Inducing Tolerance to Specific Antigen

Preserving Immune Functionality

View Our Pipeline
Cour Nanoparticle Platform

Footer

COUR Pharmaceuticals Logo
  • Our Company
  • Our Technology
  • Our Partners
  • Press
  • Careers

©

2023

COUR Pharmaceuticals.
All Rights Reserved.

Privacy Policy • Terms of Use

Back to Top